Calu-1Homo sapiens (Human)Cancer cell line

Also known as: Calu1, CALU1, Calu 1, CALU 1, Calu.1, CALU-1, CaLu-1, CALV1

🤖 AI SummaryBased on 14 publications

Quick Overview

Human lung cancer cell line used in cancer research.

Detailed Summary

Calu-1 is a human lung cancer cell line derived from a non-small cell lung carcinoma. It is widely used in research to study cancer biology, drug sensitivity, and genetic alterations. The cell line has been characterized for its expression of various proteins and has been involved in studies related to integrin expression, p16INK4a mutations, and other molecular mechanisms in cancer progression. Calu-1 is a valuable tool for investigating the genetic and molecular basis of lung cancer and for developing targeted therapies.

Research Applications

Cancer biology researchDrug sensitivity studiesGenetic and molecular analysisProteomic profilingIntegrin expression studies

Key Characteristics

Expresses p16INK4aInvolved in integrin expression studiesUsed in drug sensitivity assaysCharacterized for genetic mutations
Generated on 6/15/2025

Basic Information

Database IDCVCL_0608
SpeciesHomo sapiens (Human)
Tissue SourcePleural effusion[UBERON:UBERON_0000175]

Donor Information

Age47
Age CategoryAdult
SexMale
Racecaucasian

Disease Information

DiseaseLung squamous cell carcinoma
LineageLung
SubtypeLung Squamous Cell Carcinoma
OncoTree CodeLUSC

DepMap Information

Source TypeATCC
Source IDACH-000511_source

Known Sequence Variations

TypeGene/ProteinDescriptionZygosityNoteSource
MutationSimpleTERTc.1-124C>T (c.228C>T) (C228T)UnspecifiedIn promoterfrom parent cell line Hep-G2
MutationSimpleKRASp.Gly12Cys (c.34G>T)Unspecified-PubMed=21173094
Gene deletionTP53-Homozygous2 out of 3 copiesfrom parent cell line HL-60

Haplotype Information (STR Profile)

Short Tandem Repeat (STR) profile for cell line authentication.

Amelogenin
X
CSF1PO
10
D13S317
11,12
D16S539
11
D18S51
14,17
D19S433
13,15
D21S11
28
D2S1338
16,17
D3S1358
17
D5S818
10,12
D7S820
9,10
D8S1179
10
FGA
20,21
Penta D
9
Penta E
11
TH01
9,9.3
TPOX
8
vWA
15,16
Gene Expression Profile
Gene expression levels and statistical distribution
Loading cohorts...
Full DepMap dataset with combined data across cell lines

Loading gene expression data...

Publications

Quantitative proteomics of the Cancer Cell Line Encyclopedia.";

Sellers W.R., Gygi S.P.

Cell 180:387-402.e16(2020).

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Sellers W.R.

Nature 569:503-508(2019).

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

Cancer Res. 79:1263-1273(2019).

Chemistry-first approach for nomination of personalized treatment in lung cancer.

Posner B.A., Minna J.D., Kim H.S., White M.A.

Cell 173:864-878.e29(2018).

Characterization of human cancer cell lines by reverse-phase protein arrays.

Liang H.

Cancer Cell 31:225-239(2017).

TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.

Loewer M., Sahin U., Castle J.C.

Genome Med. 7:118.1-118.7(2015).

Comparative proteome analysis across non-small cell lung cancer cell lines.

Daub H.

J. Proteomics 130:1-10(2016).

Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies.

Golub T.R., Root D.E., Hahn W.C.

Sci. Data 1:140035-140035(2014).

A resource for cell line authentication, annotation and quality control.

Neve R.M.

Nature 520:307-311(2015).

A comprehensive transcriptional portrait of human cancer cell lines.

Settleman J., Seshagiri S., Zhang Z.-M.

Nat. Biotechnol. 33:306-312(2015).

Gene-expression data integration to squamous cell lung cancer subtypes reveals drug sensitivity.

Wu D., Pang Y., Wilkerson M.D., Wang D., Hammerman P.S., Liu J.S.

Br. J. Cancer 109:1599-1608(2013).

Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1.

Heymach J.V.

Cancer Discov. 2:798-811(2012).

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

Nature 483:603-607(2012).

A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.

Haber D.A.

Cancer Res. 70:2158-2164(2010).

Signatures of mutation and selection in the cancer genome.";

Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.

Nature 463:893-898(2010).

RASSF1A gene inactivation in non-small cell lung cancer and its clinical implication.

Mitsudomi T.

Int. J. Cancer 106:45-51(2003).

Mutations of the BRAF gene in human cancer.";

Marshall C.J., Wooster R., Stratton M.R., Futreal P.A.

Nature 417:949-954(2002).

Persistent increase in chromosome instability in lung cancer: possible indirect involvement of p53 inactivation.

Fujii Y., Takahashi T.

Am. J. Pathol. 159:1345-1352(2001).

Alterations of integrin expression in human lung cancer.";

Takahashi T., Ueda R.

Jpn. J. Cancer Res. 84:168-174(1993).

Mutations and altered expression of p16INK4 in human cancer.";

Harris C.C.

Proc. Natl. Acad. Sci. U.S.A. 91:11045-11049(1994).

Secretion of atrial natriuretic peptide and vasopressin by small cell lung cancer.

Lofters W.S., Flynn T.G.

Cancer 75:2442-2451(1995).

Presence of glycogen and growth-related variations in 58 cultured human tumor cell lines of various tissue origins.

Rousset M., Zweibaum A., Fogh J.

Cancer Res. 41:1165-1170(1981).

HLA-A, B, C and DR alloantigen expression on forty-six cultured human tumor cell lines.

Pollack M.S., Heagney S.D., Livingston P.O., Fogh J.

J. Natl. Cancer Inst. 66:1003-1012(1981).

Distinction of seventy-one cultured human tumor cell lines by polymorphic enzyme analysis.

Wright W.C., Daniels W.P., Fogh J.

J. Natl. Cancer Inst. 66:239-247(1981).

Cell surface antigens of human ovarian and endometrial carcinoma defined by mouse monoclonal antibodies.

Mattes M.J., Cordon-Cardo C., Lewis J.L. Jr., Old L.J., Lloyd K.O.

Proc. Natl. Acad. Sci. U.S.A. 81:568-572(1984).

Human tumor lines for cancer research.";

Fogh J.

Cancer Invest. 4:157-184(1986).

Absence of HeLa cell contamination in 169 cell lines derived from human tumors.

Fogh J., Wright W.C., Loveless J.D.

J. Natl. Cancer Inst. 58:209-214(1977).

One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice.

Fogh J., Fogh J.M., Orfeo T.

J. Natl. Cancer Inst. 59:221-226(1977).

New human tumor cell lines.";

Fogh J., Trempe G.L.

(In book chapter) Human tumor cells in vitro; Fogh J. (eds.); pp.115-159; Springer; New York; USA (1975).